Dabigatran derivative used as prodrug, and preparation method and application thereof

A technology of dabigatran and ester derivatives, which is applied in the field of drug synthesis and can solve the problems of low oral bioavailability of dabigatran etexilate

Inactive Publication Date: 2013-12-04
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the oral bioavailability of dabigatran etexilate is low (<6.5%), so it needs to be further improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dabigatran derivative used as prodrug, and preparation method and application thereof
  • Dabigatran derivative used as prodrug, and preparation method and application thereof
  • Dabigatran derivative used as prodrug, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 (trans) 3-(2-((3-fluoro-4-(N'-((hexyloxy)carbonyl)formamidino)phenoxy)methyl)-1-methyl-N-( Pyridin-2-yl)-1H-benzimidazole-5-carboxamido)methyl propionate (Ⅰ 2 ) preparation

[0058] 1) 3-(2-((4-cyano-3-fluorophenoxy)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzimidazole-5-carboxamide ) Synthesis of ethyl propionate (2A)

[0059] 2-(4-cyano-3-fluorophenoxy)acetic acid (1.94g, 0.01mol), EDC1 (1.9g, 0.01mol), 1-hydroxybenzotriazole (1.35g, 0.01mol) were dissolved in THF ( 35mL) and DMF (5mL) mixture. Stir in an ice-water bath for 35 min, warm to room temperature, and slowly add 1 (3.1 g, 0.009 mol) in THF (15 mL) dropwise. Add and stir for 6h. The solvent was evaporated, dichloromethane (30 mL) was added, washed with saturated brine (5 mL x 3), dried over anhydrous sodium sulfate and filtered, the filtrate was concentrated to dryness, glacial acetic acid (45 mL) was added to the residue, and heated to reflux for 2 h. Concentrate to dryness under reduced pressur...

Embodiment 2-32

[0067] With reference to the operation of Example 1, the difference is that different phenoxyacetic acids are used, and different carboxylates react with different activated ester side chains to obtain the compound of the following formula I.

[0068]

[0069]

[0070]

[0071]

[0072]

Embodiment 33

[0073] Example 33 Evaluation of Anticoagulant Activity - Determination of Activated Partial Thromboplastin Time (aPPT)

[0074] Kunming mice with a mass of 18-20 g were divided into random groups, 10 in each group, and fasted overnight. Suspend or dissolve dabigatran etexilate and the target compound to be tested in 1% aqueous solution of sodium carboxymethyl cellulose to make a concentration of 1 mg / mL, and calculate according to a dose of 10 mg / Kg (converted to dabigatran) ) for intragastric administration, half an hour later blood was collected by cardiac puncture, 4% sodium wolfberry solution was added to a final concentration of 0.4% for anticoagulation, centrifuged at 12000r / min for 5 minutes, 0.1mL of plasma was taken, 0.1mL of aPPT reagent was added, and 37°C After pre-warming for 3 minutes, add 0.1 mL of calcium chloride solution pre-warmed at 37°C, and measure the coagulation time with a platelet aggregation coagulation factor analyzer, which is the aPPT value. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation method of a benzimidazole derivative shown as a general formula I, wherein X, R, R1, R2 and R3 are defined as in the specification. The invention relates to a Dabigatran derivative shown as the general formula I and non-toxic pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing these compounds as active components, and application of the compounds and the pharmaceutical composition as thrombin inhibitors.

Description

technical field [0001] The invention relates to the field of drug synthesis, in particular to ester derivatives of dabigatran and a preparation method thereof, a pharmaceutical composition containing these derivatives and the use of the compound and the pharmaceutical composition as a thrombin inhibitor. Background technique [0002] Dabigatran etexilate (Dabigatran) is a new type of anticoagulant drug developed by Boehringer Ingelheim in Germany. In April 2008, it was first launched in Germany and the United Kingdom under the trade name of Pradaxa for the prevention and treatment of acute venous thrombosis (VTE). This is the first new oral anticoagulant drug to be marketed in 50 years after warfarin, and it is another milestone in the field of anticoagulation therapy and the prevention of potentially fatal thrombosis. The U.S. Food and Drug Administration approved Pradaxa capsules (dabigatran etexilate) on October 19, 2010 for the prevention of stroke and blood clotting in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/12A61K31/4439A61P7/02
Inventor 孔维苓蔡志强黄长江龚珉徐为人汤立达
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products